Zacks Investment Research
03 Aug 2026, 12:50 UTC · 1h ago
Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
03 Aug 2026, 12:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Supernus Pharmaceuticals reported quarterly revenues of $219.06 million, beating the Zacks Consensus Estimate by 6.84%. — Revenue beats are generally positive signals for growth and operational health, though the magnitude here is moderate.
+0.30Supernus Pharmaceuticals' year-over-year quarterly earnings declined to $0.54 per share from $0.91 per share. — A significant decline in year-over-year earnings suggests a contraction in profitability.
-0.20Supernus Pharmaceuticals reported quarterly earnings of $0.54 per share, meeting the Zacks Consensus Estimate. — Earnings that exactly meet expectations typically result in neutral market movement as the data was already priced in.
+0.00Continue reading
6 related stories
Top 1 mover · tap to explore
The stock currently carries a Zacks Rank #3 (Hold), indicating expectations that it will perform in line with the market. — A 'Hold' rating suggests a lack of strong catalyst for either a significant rally or a sharp sell-off.
+0.00Which stocks this story touches
The company beat revenue estimates and met earnings expectations, although year-over-year earnings declined.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
